30044 Federal Register / Vol. 75, No. 103 / Friday, May 28, 2010 / Notices 

Retirement; Kathy Hughes, Vice 

Chairwoman, Oneida Nation; Gail Hunt, 

President and Chief Executive Officer, 

National Alliance for Caregiving; 

Warren Jones, M.D., F.A.A.F.P., 

Executive Director, Mississippi Institute 

for Improvement of Geographic 

Minority Health; Sandy Markwood, 

Chief Executive Officer, National 

Association of Area Agencies on Aging; 

David W. Roberts, M.P.A., Vice 

President, Government Relations, 

Healthcare Information and 

Management System Society; Julie 

Boden Schmidt, M.S., Associate Vice 

President, Training and Technical 

Assistance, National Association of 

Community Health Centers; Rebecca P. 

Snead, Chief Executive Officer and 

Executive Vice President, National 

Alliance of State Pharmacy Associations 

and APME Chair; Donna Yee, PhD, 

Chief Executive Officer, Asian 

Community Center of Sacramento 

Valley; Deeanna Jang, Policy Director, 

Asian and Pacific Islander American 

Health Forum; Andrew Kramer, M.D., 

Professor of Medicine, Division of 

Health Care Policy and Research, 

University of Colorado, Denver; John 

Lui, PhD, M.B.A., Executive Director, 

Stout Vocational Rehabilitation 

Institute. 

The agenda for the June 22, 2010 

meeting will include the following: 

• Recap of the previous (March 31, 

2010) meeting. 

• Subgroup Committee Work 

Summary. 

• Medicare Outreach and Education 

Strategies. 

• Public Comment. 

• Listening Session with CMS 

Leadership. 

• Next Steps. 

Individuals or organizations that wish 

to make a 5-minute oral presentation on 

an agenda topic should submit a written 

copy of the oral presentation to the DFO 

at the address listed in the ADDRESSES

section of this notice by the date listed 

in the DATES section of this notice. The 

number of oral presentations may be 

limited by the time available. 

Individuals not wishing to make a 

presentation may submit written 

comments to the DFO at the address 

listed in the ADDRESSES section of this 

notice by the date listed in the DATES

section of this notice. 

Individuals requiring sign language 

interpretation or other special 

accommodations should contact the 

DFO at the address listed in the 

ADDRESSES section of this notice by the 

date listed in the DATES section of this 

notice. 

Authority: Sec. 222 of the Public Health 

Service Act (42 U.S.C. 217a) and sec. 10(a) 

of Pub. L. 92–463 (5 U.S.C. App. 2, sec. 10(a) 

and 41 CFR 102–3). 

(Catalog of Federal Domestic Assistance 

Program No. 93.733, Medicare—Hospital 

Insurance Program; and Program No. 93.774, 

Medicare—Supplementary Medical 

Insurance Program) 

Dated: May 13, 2010. 

Marilyn Tavenner, 

Acting Administrator, Centers for Medicare 

& Medicaid Services. 

[FR Doc. 2010–12457 Filed 5–27–10; 8:45 am] 

BILLING CODE 4120–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Advisory Committee on Immunization 

Practices (ACIP) 

In accordance with section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC) 

announces the following meeting of the 

aforementioned committee: 

Times and Dates: 

8 a.m.–6 p.m., June 23, 2010. 

8 a.m.–3 p.m., June 24, 2010. 

Place: CDC, Tom Harkin Global 

Communications Center, 1600 Clifton Road, 

NE., Building 19, Kent ‘‘Oz’’ Nelson 

Auditorium, Atlanta, Georgia 30333. 

Status: Open to the public, limited only by 

the space available. 

Purpose: The committee is charged with 

advising the Director, CDC, on the 

appropriate uses of immunizing agents. In 

addition, under 42 U.S.C. 1396s, the 

committee is mandated to establish and 

periodically review and, as appropriate, 

revise the list of vaccines for administration 

to vaccine-eligible children through the 

Vaccines for Children (VFC) program, along 

with schedules regarding the appropriate 

periodicity, dosage, and contraindications 

applicable to the vaccines. 

Matters To Be Discussed: The agenda will 

include discussions on: Evidence based 

recommendations; human papillomavirus 

(HPV) vaccines; 13-valent pneumococcal 

conjugate vaccine; meningococcal vaccine; 

hepatitis vaccines; a vaccine supply update; 

respiratory syncytial virus 

immunoprophylaxis vaccine; rotavirus 

vaccines; pertussis vaccine; and influenza 

vaccines. Agenda items are subject to change 

as priorities dictate. 

Contact Person for More Information: 

Antonette Hill, Immunization Services 

Division, National Center for Immunization 

and Respiratory Diseases, CDC, 1600 Clifton 

Road, NE., (E–05), Atlanta, Georgia 30333, 

telephone 404/639–8836, fax 404/639–8905. 

The Director, Management Analysis and 

Services Office, has been delegated the 

authority to sign Federal Register notices 

pertaining to announcements of meetings and 

other committee management activities for 

both CDC and the Agency for Toxic 

Substance and Disease Registry. 

Dated: May 20, 2010. 

Elaine L. Baker, 

Director, Management Analysis and Services 

Office, Centers for Disease Control and 

Prevention. 

[FR Doc. 2010–12818 Filed 5–27–10; 8:45 am] 

BILLING CODE 4160–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Partnerships To Advance the National 

Occupational Research Agenda 

(NORA) 

AGENCY: The National Institute for 

Occupational Safety and Health 

(NIOSH) of the Centers for Disease 

Control and Prevention (CDC), 

Department of Health and Human 

Services (HHS). 

ACTION: Notice of public meeting. 

SUMMARY: The National Institute for 

Occupational Safety and Health 

(NIOSH) of the Centers for Disease 

Control and Prevention (CDC) 

announces the following public 

meeting: ‘‘Partnerships to Advance the 

National Occupational Research Agenda 

(NORA)’’. 

Public Meeting Time and Date: 

10 a.m.–4 p.m. EDT, June 16, 2010. 

Place: Patriots Plaza, 395 E. Street, 

SW., Conference Room 9000, 

Washington, DC 20201. 

Purpose of Meeting: The National 

Occupational Research Agenda (NORA) 

has been structured to engage partners 

with each other and/or with NIOSH to 

advance NORA priorities. The NORA 

Liaison Committee continues to be an 

opportunity for representatives from 

organizations with national scope to 

learn about NORA progress and to 

suggest possible partnerships based on 

their organization’s mission and 

contacts. This opportunity is now 

structured as a public meeting via the 

internet to attract participation by a 

larger number of organizations and to 

further enhance the success of NORA. 

Some of the types of organizations of 

national scope that are especially 

encouraged to participate are employers, 

unions, trade associations, labor 

associations, professional associations, 

and foundations. Others are welcome. 

This meeting will include updates 

from NIOSH leadership on NORA as 

well as updates from approximately half 

of the NORA Sector Councils on their 

progress, priorities, and implementation 


jlentini on DSKJ8SOYB1PROD with NOTICES
Federal Register / Vol. 75, No. 103 / Friday, May 28, 2010 / Notices 30045 

plans to date, including the NORA 

Construction, Manufacturing, Public 

Safety, Services, and Wholesale and 

Retail Trade Councils. Updates will also 

be given on cross-sector activities in the 

areas of Healthy People 2020 and the 

WorkLife Initiative. After each update, 

there will be time to discuss partnership 

opportunities. 

Status: The meeting is open to the 

public, limited only by the capacities of 

the conference call and conference room 

facilities. There is limited space 

available in the meeting room (capacity 

34). Therefore, information to allow 

participation in the meeting through the 

internet (to see the slides) and a 

teleconference call (capacity 50) will be 

provided to registered participants. 

Participants are encouraged to consider 

attending by this method. Each 

participant is requested to register for 

the free meeting by sending an e-mail to 

noracoordinator@cdc.gov containing the 

participant’s name, organization name, 

contact telephone number on the day of 

the meeting, and preference for 

participation by Web meeting 

(requirements include: Computer, 

internet connection, and telephone, 

preferably with ‘mute’ capability) or in 

person. An e-mail confirming 

registration will include the details 

needed to participate in the Web 

meeting. Non-US citizens are 

encouraged to participate in the web 

meeting. Non-US citizens who do not 

register to attend in person on or before 

June 2, 2010, will not be granted access 

to the meeting site and will not be able 

to attend the meeting in-person due to 

mandatory security clearance 

procedures at the Patriots Plaza facility. 

Background: NORA is a partnership 

program to stimulate innovative 

research in occupational safety and 

health leading to improved workplace 

practices. Unveiled in 1996, NORA has 

become a research framework for the 

nation. Diverse parties collaborate to 

identify the most critical issues in 

workplace safety and health. Partners 

then work together to develop goals and 

objectives for addressing those needs 

and to move the research results into 

practice. The NIOSH role is facilitator of 

the process. For more information about 

NORA, see http://www.cdc.gov/niosh/ 

nora/about.html. 

Since 2006, NORA has been 

structured according to industrial 

sectors. Eight major sector groups have 

been defined using the North American 

Industrial Classification System 

(NAICS). After receiving public input 

through the web and town hall 

meetings, ten NORA Sector Councils 

have been working to define sectorspecific strategic plans for conducting 

research and moving the results into 

widespread practice. During 2008–2009, 

most of these Councils have posted draft 

strategic plans for public comment. 

Seven have posted finalized National 

Sector Agendas after considering 

comments on the drafts. For more 

information, see the link above and 

choose ‘‘Sector-based Approach,’’ 

‘‘NORA Sector Councils,’’ ‘‘Sector 

Agendas’’ and ‘‘Comment on Draft Sector 

Agendas’’ from the right-side menu. 

FOR FURTHER INFORMATION CONTACT: 

Sidney C. Soderholm, PhD, NORA 

Coordinator, E-mail 

noracoordinator@cdc.gov, telephone 

(202) 245–0665. 

Dated: May 20, 2010. 

Tanja Popovic, 

Deputy Associate Director for Science, 

Centers for Disease Control and Prevention. 

[FR Doc. 2010–12743 Filed 5–27–10; 8:45 am] 

BILLING CODE 4163–19–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2010–N–0001] 

Oncologic Drugs Advisory Committee; 

Notice of Meeting 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

This notice announces a forthcoming 

meeting of a public advisory committee 

of the Food and Drug Administration 

(FDA). The meeting will be open to the 

public. 

Name of Committee: Oncologic Drugs 

Advisory Committee. 

General Function of the Committee: 

To provide advice and 

recommendations to the agency on 

FDA’s regulatory issues. 

Date and Time: The meeting will be 

held on July 20, 2010, from 8 a.m. to 3 

p.m. 

Location: Hilton Washington DC 

North/Gaithersburg, The Ballrooms, 620 

Perry Pkwy., Gaithersburg, MD. The 

hotel telephone number is 301–977– 

8900. 

Contact Person: Nicole Vesely, c/o 

Melanie Whelan, Food and Drug 

Administration, 10903 New Hampshire 

Ave., Bldg. 51, rm. 6100, Silver Spring, 

MD 20993–0002, FAX: 301–847–8737, 

to reach by telephone before June 8, 

2010, please call 301–827–7001; to 

reach by telephone after June 8, 2010, 

please call 301–796–9001, e-mail: 

nicole.vesely@fda.hhs.gov, or FDA 

Advisory Committee Information Line, 

1–800–741–8138 (301–443–0572 in the 

Washington, DC area), code 

3014512542. Please call the Information 

Line for up-to-date information on this 

meeting. A notice in the Federal 

Register about last minute modifications 

that impact a previously announced 

advisory committee meeting cannot 

always be published quickly enough to 

provide timely notice. Therefore, you 

should always check the agency’s Web 

site and call the appropriate advisory 

committee hot line/phone line to learn 

about possible modifications before 

coming to the meeting. 

Agenda: On July 20, 2010, the 

committee will discuss supplemental 

biologics license applications (sBLAs) 

125085/191 and 192 for AVASTIN 

(bevacizumab), manufactured by 

Genentech, Inc. The two proposed 

indications (uses) for this product are: 

(1) First-line treatment of a subgroup of 

women with metastatic breast cancer 

known as HER2-negative breast cancer, 

in combination with the chemotherapy 

drug docetaxel; and (2) first-line 

treatment of HER2-negative metastatic 

breast cancer in combination with one 

of two classes of chemotherapy drugs, 

known as taxanes and anthracyclines, or 

with the chemotherapy drug, 

capecitabine. In addition to the 

discussion of these two indications, the 

committee will also consider the impact 

of the submitted studies on the 

conversion from accelerated to regular 

approval of the indication for the 

treatment, in combination with the 

chemotherapy drug paclitaxel, of 

patients who have not received 

chemotherapy for their locally recurrent 

or metastatic HER2 negative breast 

cancer. 

FDA intends to make background 

material available to the public no later 

than 2 business days before the meeting. 

If FDA is unable to post the background 

material on its Web site prior to the 

meeting, the background material will 

be made publicly available at the 

location of the advisory committee 

meeting, and the background material 

will be posted on FDA’s Web site after 

the meeting. Background material is 

available at http://www.fda.gov/ 

AdvisoryCommittees/Calendar/ 

default.htm. Scroll down to the 

appropriate advisory committee link. 

Procedure: Interested persons may 

present data, information, or views, 

orally or in writing, on issues pending 

before the committee. Written 

submissions may be made to the contact 

person on or before July 6, 2010. Oral 

presentations from the public will be 

scheduled between approximately 12:30 

p.m. to 1:30 p.m. Those desiring to 

make formal oral presentations should 


jlentini on DSKJ8SOYB1PROD with NOTICES